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A B S T R A C T
Disease-modifying therapies capable to stop or slow Parkinson’s disease (PD) progression are still elusive
due to severe shortcomings in the understanding of PD etiopathogenesis as well as limitations in routine
clinically-based diagnosis precluding PD detection during its early course. Proteomics has recently
emerged as one of the most attractive approaches to unravel the complex nature of PD processes and
investigate PD potential biomarkers. In contrast to traditional candidate-based studies, it offers global
and high-throughput strategies to systematically analyze proteins – the pathological effectors
themselves – without the need to establish a priori hypotheses. This review aims to summarize the
latest advances in PD research in the context of proteomics. After an overview of some methodological
aspects, the most recent PD-related ﬁndings will be discussed together with the limitations and
perspectives of current proteomic workﬂows.
ã 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder, affecting adult individuals of all races and
culture. The progressive deterioration of motor function, manifested
clinically by various degrees of tremor at rest, rigidity, slowness of
movement (bradykinesia) and postural instability, appears after a
signiﬁcant loss of dopaminergic neurons in the substantia nigra (SN)
pars compacta has been reached. Nigral neurodegeneration together
with the presence of distinctive intracytoplasmic inclusions referred
to as Lewy bodies (LB) in the surviving neurons are the two
invariant pathological hallmarks of PD which are mandatory to
establish a deﬁnitive diagnosis at autopsy. Non-motor symptoms
encompassing cognitive decline, anxiety, sleep disturbances, or
autonomic impairment are increasingly recognized to be part of the
PD clinical spectrum and may result from the vulnerability of
selected neuronal populations in numerous regions of the central
and autonomous nervous systems.
Altogether, PD results in major functional disabilities impacting
quality of life, working capacity and life expectancy with mortality
rates being nearly doubled in PD versus aged-matched subjects
[1–3]. Despite the remarkable efﬁcacy of dopamine replacement
therapy to alleviate motor symptoms and improve patients’ quality
of life, PD remains incurable without any treatment available to
modify or stop the disease’s rampage through the nervous system.
The estimated direct and indirect costs related to the illness ranks
high among brain disorders, amounting up to 13.9 billion euros in
Europe for the year 2010 alone [4]. The number of PD cases, which
currently approximates 1.2 million in Europe (0.3% of the general
population) and 1 million in the USA, is expected to double by year
2030 along with the increase of life expectancy in the Western
populations [4–6]. In the absence of any disease-modifying
therapy yet, the socioeconomic and ﬁnancial burdens incurred
by PD will continue to grow and defy our healthcare system over
the coming decades.
Before any preventive or curative intervention could be designed,
a clear and detailed understanding of the molecular mechanisms
underlying neurodegeneration in sporadic PD is required. However,
despite decades of research, this is deﬁnitely not the case yet.
Many mechanisms have been shown to sensitize neurons to death,
including impairment of protein degradation systems,
mitochondrial dysfunction and oxidative stress, inﬂammation,
excitotoxicity or enhanced apoptosis. In all likelihood, more than
one of these, and possible many others, might be at work in PD but
the precise combination and temporal succession of the molecular
events leading to cell death remain to be disentangled.
Thus far, research into PD pathogenesis has heavily relied upon
toxic and transgenic animal models, the engineering of which has
derived from rare neurotoxin-induced and monogenic forms of
parkinsonism in humans. However, these hypothesis-driven
approaches have demonstrated major limitations, casting serious
doubts about the validity of such models to address the complexity
of PD pathogenesis. The recent emergence of more global, unbiased
and hypothesis-free disciplines such as GWAS and “omics” may
provide new research paradigms to explore PD pathogenesis and
PD biomarkers, which may respectively pave the way for original
neuroprotective or neuroregenerative therapeutic targets and offer
early and accurate diagnostic tools. After reappraising some key
aspects of PD neuropathology and etiopathogenesis, this reviewaims to summarize the ultimate advances in PD research in
the context of proteomics. We will glance over proteomics
techniques from sample preparation to mass spectrometry (MS)
analysis before examining the most recent PD-related ﬁndings,
limitations and future directions.
2. PD neuropathology: the disease substrates
2.1. Neuropathological hallmarks
Most available evidence suggests that the lesional core of PD
pathology is the damage of dopaminergic cells in the SN pars
compacta [7], which results in dopamine (DA) depletion in the
striatum and destabilization of the basal ganglia (BG) motor
control loops [8]. Nigral neurodegeneration is thus unambiguously
linked to motor symptoms, which ﬁrst become apparent when
about 80% of striatal dopaminergic terminals and 50–60% of nigral
dopaminergic cell bodies are already lost [9,10]. In the SN, neuronal
loss is greater in the calbindin D28K-poor compartments termed
nigrosomes than in the calbindin D28K-enriched matrix. The degree
of neuronal loss is related to disease duration and follows a
stereotyped spatiotemporal progression (from the more caudal
nigrosome N1 > N2 > N4 > N3 to the more rostral nigrosome N5)
[11] consistently observed across PD patients and differing from
normal aging or other neurodegenerative disorders [7]. While
neuronal loss is particularly severe within the SN ventrolateral tier,
involvement of other midbrain dopaminergic cell populations
(medial and medioventral, A8, substantia nigra pars lateralis,
central gray substance) is less pronounced and may rather reﬂect
some physiological aging-related decline [12].
Surviving nigral neurons frequently exhibit cytoplasmic protein
inclusions referred to as LB or Lewy neurites if located in neuronal
processes, which contain, among many others proteins, misfolded
a-synuclein (a-SYN) and ubiquitin (Ub) [13]. It is still unclear if LBs
themselves are the pathological entities interfering with normal
cell function, if they represent a cytoprotective mechanism
similarly to aggresomes or a failed attempt to eliminate cytotoxic
proteins such as misfolded a-SYN. The percentage of LB-bearing
nigral cells appears to be stable over time (3.6% in average),
suggesting that they are eliminated as the disease progresses when
the afﬂicted neurons die. Thus, in the SN at least, LB may be closely
related to nigral neuronal loss [14]. Current knowledge on LB
structure, formation, composition and role in cell death is still
limited and reviewed elsewhere (in [15]). Of note, LBs are not
speciﬁc for PD, as they are found in other forms of parkinsonism
collectively termed “synucleopathies” (i.e., dementia with LB,
multiple system atrophy), in Alzheimer’s disease (AD), as well as
incidentally in aged people [16].
2.2. Extranigral aspects of PD and Braak staging
Neuronal loss and LB formation are neither conﬁned to the
midbrain and the SN, nor restricted to the dopaminergic
neurochemical system. Based on neuropathological studies, PD is
now rather viewed as a multisystem disorder affecting numerous
neuronal populations both in the central and peripheral nervous
systems [17]. Dopaminergic neurons found outside the midbrain
are unequally vulnerable to PD, partially lost in the retina [18]
and enteric nervous system [19] while relatively spared in the
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coeruleus), cholinergic (i.e., dorsal motor nucleus of the vagus nerve
(DMV), nucleus basalis of Meynert), serotoninergic (i.e., raphe
nuclei) or glutamatergic (i.e., amygdala, cortex) systems are also
affected in anatomical regions of predilection within the brain as
well as nerve and ganglia of the autonomic system [17]. Clinico-
pathological correlations suggest that the neurodegenerative
process extension beyond the BG structures may be responsible
for numerous non- motor signs not attributable to nigrostriatal
degeneration such as sleep disorders, dementia, depression and
autonomic dysfunction (i.e., cardiovascular, gastrointestinal) [21].
Table 1 provides a non-exhaustive overview of susceptible CNS and
ANS neuronal populations affected in PD, together with their known
or putative clinical correlates.
PD pathology requires years to reach its full extent throughout
the nervous system and the temporal relationships of the lesions are
still not well established. Braak and co-workers proposed a
neuroanatomical staging system based on a-SYN immunoreactivity
distribution in the brains of PD patients and clinically asymptomatic
incidental Lewy pathology cases. The authors predicted that PD
pathology follows a stereotyped and selective caudo-rostral
progression within vulnerable structures of the CNS (Table 1). In
this scenario, the disease begins in the DMV and in the olfactory bulb
(Braak 1), ascends in the brainstem to reach the raphe nuclei and the
locus coeruleus (Braak 2) before affecting the SN (Braak 3). Finally,Table 1
Anatomical sites of PD pathology and clinical correlates (adapted from [28]).
Anatomical site Neuro-transmitter Lewy p
Autonomic nervous system
Ganglia and nerve ﬁbers
&Gastroesophagal
Submandibular gland ACh U 
Myenteric and submucosal plexus (i.e., oesophagus,
stomach, colon)
ACh, DA U 
&Sympathetic chain
Cardiac plexus NA U 
&Adrenal gland A, NA U 
Spinal cord
&Intermediolateral n. ACh U 
Medulla
&Dorsal motor n. of glossopharyngeus and
vagus (IX/X)
ACh U 
Central nervous system
Retina
&Inner plexiform layer DA  
Olfactory bulb
&Anterior olfactory n. ACh, CRF U 
Pons U 
&Locus ceruleus, raphe and pedonculopontine n. NA, 5-HT, ACh U 
Midbrain
&Substantia Nigra DA U 
Hypothalamus
&Supraoptic and paraventricular n. Oxy, VP  
&Tuberomamillary and lateral tuberal n. HistHyct U 
&Hypocretin cells (perifornical)  
Thalamus
&Intralaminar n. (centromedian and parafascicular,
parataenial)
Glu U 
Basal forebrain
&N. basalis of Meynert ACh U 
&Amygdala (cortical and basolateral n.) CCK, Glu U 
&Hippocampus Glu U 
Cerebral cortex
&Frontal cortex Glu U 
&Parietal cortex Glu U 
Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); A, adrenaline, ACh, acetylch
Glu, glutamate; Hist, histamine; Hyct, hypocretin; n., nucleus; NA, noradrenaline; Oxy,in later stages (Braak 4–6), the disease enters the temporal
mesocortex and eventually the neocortex. Stage 1 and 2 are
considered as pre-motor stages, with motor symptoms emerging
only in stage 3 when SN neurodegeneration begins [17,22].
The predictive validity of Braak’s concept of neuropathological
staging has been somehow disputed as it does not seem to
correlate with PD clinical severity and duration [23]. In fact, there
is a considerable variability in the temporal sequence and
topographical distribution of Lewy pathology among patients.
Some studies have reported cases of aged individuals dying with
Braak stages 4–6 without any clinical record of neurological
impairment [24–26]. Moreover, the relationship between Lewy
pathology and neuronal dysfunction or death is still uncertain,
representing an additional challenge for the Braak’s hypothesis.
Although Braak’s staging might require further clinical and
pathological validation, it is still widely accepted as it broadly
concurs with clinical observations and might be accurate in about
80% of the cases [27]. A more sensitive PD staging system might
include neurodegeneration patterns in addition to Lewy pathology.
2.3. Is PD a prion-like disorder?
Braak and co-workers suggested that an unknown environ-
mental insult initiates the pathological process, which may spread
trans-synaptically from one susceptible brain region to another viaathology Neuronal loss Braak stage Clinical symptoms Ref.
 Sialorrhea, dysphagia [29]
 Esophageal and gastric
dysfunction, constipation
[30–32]
U Cardiac denervation,
orthostatic hypotension
[33–35]
 Autonomic dysfunction,
hypotension?
[36]
U Orthostatic hypotension [37]
U 1 Esophageal and gastric
dysmotility
[17]
U Visual disturbances [38,39]
U 1 Hyposmia [17]
U
U 2 Sleep disorders, depression,
akinesia?
[17]
U 3 Bradykinesia, rigidity,
tremor
[17]
U 3 [39,40]
 Hypotension? [41,42]
U Sleep disturbances [43]
U 3 Motor impairments [44,45]
U 4 Cognitive impairment [17]
U 4 Visual hallucinations?
Hyposmia?
[46]
U 4 Mild cognitive impairment [17]
U 5 Dementia [17]
 6 Dementia [17]
oline; CRF, corticotrophin-releasing factor; CCK, cholecystokinin;DA, dopamine;
 Oxytocin; VP, vasopressin;
p
, present;  , not conﬁrmed or absent.
4 V. Licker, P.R. Burkhard / Translational Proteomics 4–5 (2014) 1–17thin, long and unmyelinated axons [28]. CNS may be accessed
through both a nasal and a gastric route via preganglionic ﬁbers of
the DMV which innervate the enteric nervous system [47–49]. This
hypothesis ﬁts with the neuropathological evidence of LB in the
olfactory and enteric systems of both PD and incidental cases
[32,50,51] as well as the clinical observations of olfactory deﬁcit
and gastrointestinal dysfunction in PD patients, which precede the
disease motor onset [52,53].
a-SYN itself may be the pathogenic factor underlying the spread
of Lewy pathology throughout the CNS following a prion-like
process. This hypothesis has ﬁrst been proposed after observing
that fetal mesencephalic cells grafted into the brain of PD patients
11–22 years earlier contained classical LB inclusions [54–56]. This
suggested that a-SYN could be transmitted from the affected host
neurons to healthy transplanted neurons, where it recruited normal
a-SYN to misfold. Other ﬁndings derived from tissue culture and
transgenic animals demonstrated cell-to-cell transfer of a-SYN
inducing pathological changes and cell death in the recipient
[48,57]. Recently, Luk and co-workers demonstrated the
widespread propagation of pathological a-SYN aggregates
throughout anatomically connected regions of the CNS following
brain injection of synthetic a-SYN ﬁbrils into a-SYN transgenic or
wild type nontransgenic mice [58]. They suggested a mechanistic
link between a-SYN transmission and PD hallmarks as a- SYN
pathology resulted in the progressive loss of DA nigral neurons and a
consecutive striatal dopamine depletion of sufﬁcient magnitude to
induce detectable motor deﬁcits [59].
Accumulating evidence suggests that PD may indeed be a
prion-like disorder and that a-SYN behaves like the protein
prion (PrP), which underlies disorders such as Creutzfeld–Jakob
disease or bovine spongiform encephalopathy. Both proteins share
many similarities: (i) they can undergo an aberrant conformational
change from a native a-helix to a b-sheet conformation which
promotes their self-aggregation, (ii) their protein aggregates can
act as “seeds” to recruit and promote the misfolding of wild-type
proteins, (iii) their misfolded protein form is recognized to be toxic
and induce neurodegeneration [60]. The transmission of LB
pathology following a prion-like mechanism through anatomically
linked neuronal network might explain the sequential and
predictable topographical progression of PD observed by Braak
and co-workers. The mechanisms by which intracellular protein
aggregates can reach neighboring cells in the CNS are not clear,
and may involve neuronal transmission by exocytosis and
endocytosis as well as spreading throughout the nervous system
via anterograde and retrograde transport.
3. Etiological aspects of PD
Among the many hypotheses surrounding PD etiology, environ-
mental toxin exposure has been the most studied. The awareness of a
relationship with PD was raised during the 1980s, when young
individuals developed PD signs after an intake of designer drugs
contaminated with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine
(MPTP), a substance similar to the herbicide paraquat [61]. MPTP was
then demonstrated to selectively damage nigral neurons by blocking
mitochondrial complex I [62]. Since then, many pesticides
(i.e., rotenone), herbicides (i.e., paraquat) or insecticides were
positively associated to PD risk [63]. Although many environmental,
occupational and life-style risk factors were proposed, older age still
remains the most signiﬁcant and well documented one. Conversely,
epidemiological data suggest the existence of protective factors
such as cigarette smoking and coffee drinking [64], the use of
non-steroidal anti- inﬂammatory (NSAID) drugs [65] or high uric
acid levels [66]. As PD prevalence and incidence are lower inwomen,
sex hormones such as estrogens have been suggested to exhibit
neuroprotective antioxidant properties [67].A clear mendelian inheritance can be established in 5–10% of
patients. Familial forms constitute a particular category of PD cases
often displaying uncommon clinical symptoms – such as young
onset or dystonias – and an absence of LB. The ﬁrst PD mutation
was identiﬁed in SNCA – the gene encoding a-SYN – in 1997 [68],
with additional point mutations, duplications and triplications
identiﬁed in other kindreds with autosomal dominant PD [69–71].
Interestingly, a-SYN protein turned out to be a major component of
LB [72] and SNCA duplications were recently associated to sporadic
PD cases [73]. Since then, 6 causative genes have been associated to
autosomal dominant (i.e., SNCA, UCHL-1, LRRK2) or autosomal
recessive (i.e., Parkin, PINK1, DJ-1) PD and extensively reviewed in
[74]. Two novel autosomal dominant genes, VPS35 (PARK17) [75]
and EIF41 (PARK18) [76] were recently found in kindreds
presenting with late-onset typical PD.
It must be stressed, however, that the vast majority of PD cases are
sporadic and may rather be caused bya complex interactionbetween
genetic susceptibility and environmental factors [77]. A few PARK
genes such as SNCA [78] or LRRK2 [79], as well as genes involved in
other neurodegenerative diseases including MAPT (microtubule
associated protein tau) [80] or GBA (glucocerebrosidase) [81] appear
to impact PD susceptibility signiﬁcantly. To date, more than 800
genetic association studies have been published to decipher the
missing heritability in PD, often exhibiting inconsistent results [82].
Meta-analyses were recently performed showing genome-wide
statistically very signiﬁcant association of eleven loci BST1,
CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3,
PARK16, SNCA, STK39, and SYT11/RAB25 and novel evidence for
ITGA8 polymorphism [82]. However, at the very best, only 60% of the
population-attributable risk might be explained by the most
promising PD loci identiﬁed until now [83].
4. PD research challenges
4.1. Deciphering PD pathogenesis
Despite clues provided by recent genetic breakthroughs and the
many alterations observed in the brain of idiopathic PD cases, the
molecular mechanisms underlying sporadic PD etiopathogenesis
and particularly the massive and selective neurodegeneration in
the SN still need to be deciphered. Over the last decades, a
variety of neurotoxin-induced and transgenic animals have been
constructed to model PD. Although some of these show a massive
SN degeneration and a clear PD phenotype, they are less useful to
address PD pathogenesis as toxin exposure, for example to
pesticides, is by no means a prerequisite for PD to develop. More
recently, a variety of transgenic mice have been developed using
different strategies, the most common being to incorporate and
overexpress mutated genes known to be associated with rare
monogenic forms of parkinsonism in humans [84]. So far, however,
none of these models has been able to recapitulate all key features
of PD [85]. Importantly, most transgenic models have failed to
induce signiﬁcant SN degeneration, LB formation and a clear PD
phenotype [86]. In addition, this candidate-based research
paradigm is problematic as most PD patients do not exhibit
pathogenic gene mutations at the basis of their condition, and,
perhaps with the exception of a-SYN, it remains to be established
to which extent molecular abnormalities observed in monogenic
PD and their animal counterparts are truly relevant to study those
underlying sporadic PD.
4.1.1. Pathogenetic mechanisms of PD at a glance
It is generally thought that a combination of environmental
factors along with aging initiate a cascade of pathological cellular
and molecular events ultimately leading to neuronal demise in
genetically susceptible individuals. Many mechanisms have been
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succession of events at work in PD still need to be established.
Table 2 summarizes some of the major evidence supporting
common hypotheses surrounding PD pathogenesis, which were
gathered from recent studies of sporadic and familial PD cases as
well as animal models of PD.
Brain deposition of insoluble aggregates containing abnormal
proteins, which results in the formation of neuronal intra-
cytoplasmic LB in PD, is a hallmark of many neurodegenerative
disorders and as such, may underlie a common pathogenic
mechanism of neuronal death. Alpha-SYN, whose gene was found
mutated in inherited automosal dominant PD cases, seems to play
a central role in sporadic PD as it notably turned out to be a major
constituent of LB. The mechanisms of aggregation and protein
toxicity in PD remain unclear but multiple studies suggest that
a-SYN overexpression or misfolding resulting from mutations orTable 2
Common PD pathogenic hypotheses and their arguments.
PD pathogenic hypothesis Major evidence
Sporadic PD 
Protein aggregation, Lewy Bodies (LB) and a-SYN
Hypothesis: misfolded or abnormally modiﬁed proteins such
as a-SYN can accumulate, resulting in LB formation and
neurodegeneration. Mechanisms of toxicity are unknown:
a-SYN oligomers? LB?
& a-SYN is a major LB
& GWAS association of
& SNCA duplications in
Protein degradation system impairment
Hypothesis: Dysfunction in main protein degradation systems
(UPS and ALP) may lead to protein accumulation, LB
formation and neurodegeneration.
& Both UPS and ALP ar
& Ubiquitin proteasome system (UPS) & Altered proteasomal
peripheral blood cells 
& UPS and ubiquitinat
& Autophagy-lysosomal pathway (ALP) & Accumulation of und
autophagosomes in ni
[102] and alterations o
markers
&GWAS association of 
Mitochondrial dysfunction
Hypothesis: Mt. dysfunction leads to decreased ATP levels and
increased ROS production, which may promote high-energy
demanding neuron impairment.
&Mt complex I activity
[105], platelets [106], f
& Higher amount of m
DA neurons from PD p
Oxidative stress (OS)
Hypothesis: OS induce oxidative damage through free radical
(NO, ROS) increase and subsequent neuronal death.
& Alterations in brain 
antioxidant defenses (
& Oxidative damage to
a-SYN nitration [87]) 
Inﬂammation/glial reaction
Hypothesis: Inﬂammation is involved in self-perpetuating
deleterious events that lead to neurodegeneration.
& Increased pro- inﬂam
enzymes (i.e., TNF-a, i
brains [116–118]
& Anti-inﬂammatory d
are protective [121]
Abbreviations: COX2, cyclo-oxygenase 2; DA, dopamine; iNOS, inducible nitric oxid synth
mt, mitochondrial; OS, oxidative stress; TNF, tumor necrosis factor alpha. Gene namespost-translational modiﬁcations (i.e., nitration, phosphorylation,
ubiquitination) may confer toxic properties to the protein and
increase its propensity to aggregate [123]. In fact, a-SYN aberrant
soluble oligomeric conformations also known as protoﬁbrils might
be the more toxic entities. Increasing numbers of aggregation-
prone proteins are being identiﬁed in LB such as parkin, indicating
that a-SYN might not be the only key player. Unraveling the exact
composition of LB could provide some clues on other proteins
potentially playing a role in PD neurotoxicity.
Under pathological conditions such as proteostatic impairment
or during normal aging, the propensity to protein misfolding and
aggregation might be enhanced. Several lines of evidence suggest
that dysregulation of the main cellular protein degradation
pathways – ubiquitin proteasome system (UPS) and autophagy-
lysosomal pathways (ALP) – leads to abnormal protein accumulation
and cellular toxicity in PD. UPS mediates the selective degradation ofFamilial PD PD models
 component [72]
 SNCA [82]
 rare cases [73]
& SNCA
duplication,
triplication
[69–71]
& Mutations
A53T, A30P,
E46K [68]
& a-SYN mutations, post-translational
modiﬁcations [87–89], truncation [90]
increasea-SYN aggregation
& a-SYN deletion confers neurotoxicity
resistance [91]
& a-SYN over-expression in rodents and
non-human primates can induce DA
neuronal death [92,93]
& Brain injection of a-SYN ﬁbrils in wt mice
induce nigral neurodegeneration and PD-
like clinical features [59]
e decreased in aging brains & Both UPS and ALP may degrade a-SYN
[94]
& Pathologic a-SYN can impair UPS and ALP
[95,96]
 activity in SN, or
[97,98]
& Parkin,
UCHL-1
& Proteasome function altered by exposure
to toxins (MPTP, rotenone) or high levels of
a-SYN [99]
ed proteins in LB & Proteasome inhibition induce protein
aggregation and neurodegeneration in vitro
and in vivo [100,101]
egraded
gral DA neurons
f lysosomal
& ATP13A2,
LRRK2
& Loss of autophagy-related gene (atg7)
results in protein accumulation and DA
neurodegeneration [103]
lysosomal GBA [81] & Parkin and
PINK-1
& Parkin and PINK-1 may regulate
mitophagy [104]
 deﬁciency (i.e., SN
rontal cortex [107])
& PINK1,
Parkin, LRRK2,
DJ-1, omi/
Htra2
& Inhibition of mt complex I activity by
toxins (i.e., MPTP, rotenone) induce
neurotoxicity [108]
tDNA mutations in
atients [109]
& POLG
[110,111]
& Deletion of mttranscription factor TFAM
induce DA neurodegeneration [112]
iron content,
i.e., DJ-1, SOD))
& DJ-1 & Intracellular [113], intra-mt [114], or
extracellular [115] free radicals mediate DA
neurodegeneration in PD models . lipids, proteins (i.e.
and DNA
matory factors and
NOS, COX2) in PD
& a-SYN overexpression induce
inﬂammation [119]
& Inhibition of microglial activation prevent
neuronal loss [120]
rugs (i.e., NSAID) & LPS mediated inﬂammation induce nigral
DA neurodegeneration [122]
ase; LPS, lipopolysaccharides; MPTP,1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
 are in italic.
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chains, through the sequential action of several enzymes
(E1, E2, E3). ALP is primarily involved in the degradation of long-lived
stable intracellular proteins as well as protein aggregates and
organelles [71] via lysosome delivery [124–126] and might
constitute a default degradation pathway when UPS is inhibited
[127]. Evidence of their impairment in sporadic PD came from the
observation of proteasome-related proteins in LB (i.e., ubiquitinated
proteins,proteasome components)aswellasdecreasedproteasomal
activity and signs of abnormal autophagy in PD brains compared to
controls [97,102,128]. Further underlining their importance in PD,
they both seem to be involved in a-SYN clearance [94,96]. In
addition, recent functional studies demonstrated that many proteins
linked to monogenic PD families may be involved in UPS (i.e., E3
ligase Parkin) or autophagy pathways (i.e., lysosomal ATPase
ATP13A2, PINK1) [99,129–131]. Interestingly, Parkin, and PINK-1
have been reported to participate in signaling pathways controlling
mitophagy [132], an essential mitochondria quality control process
whereby damaged mitochondria can be removed. It is however still
unclear whether these changes mediate neuronal cell survival or
death response.
PD pathogenesis has long been associated to mitochondrial
dysfunction and oxidative stress. Mitochondria assume a plethora of
essential cellular functions whose alteration might lead to cell
demise through ATP energy depletion, increased ROS formation and
oxidative stress, or Ca2+ homeostasis imbalance. In pathological
conditions, a vicious cycle might install whereby damaged
mitochondria are in turn a source and a target of ROS, ultimately
leading to neuronal loss. Other sources of oxidative stress include
DA metabolism, reactive iron deposition, impaired antioxidant
pathways or inﬂammation processes among others. In sporadic PD,
their role is notably supported by the reduced mitochondrial
complex I activity and increased oxidative levels observed in PD
brains [87,133–135]. Substantial insights in the understanding of
mitochondrial role and oxidative stress in PD came from the
identiﬁcation of PD-associated genes encoding mitochondrial
related proteins PINK1, DJ1, parkin, LRRRK2, a-SYN, or omi/Htra2,
whose alterations were shown to affect mitochondrial integrity or
increase oxidative damage [108,136]. Recent ﬁndings suggest that
mutations in the mitochondrial genome (mtDNA), which encodes
proteins from the respiratory chain, are also involved in PD
pathogenesis.
Inﬂammation likely contributes to the cascade of events leading
to DA neuron death in PD, through mechanisms comprising
astrogliosis, microglial activation or lymphocytes inﬁltration [137].
Epidemiological studies have suggested that inﬂammatory
process can be a risk factor for PD, as regular consumers of non-
steroidal anti-inﬂammatory drugs (NSAIDs) are relatively spared
by PD [121,138] and both cellular and molecular post-mortem
studies reported inﬂammatory features in parkinsonian brains
[116–118,139–141]. Mechanisms of neurotoxicity may involve the
activation of cellular death pathways in DA neurons through the
microglia cell release of deleterious pro-inﬂammatory compounds
(i.e., cytokines) or indirectly through the production of microglial-
derived free radicals (i.e., NO) [142]. A vicious cycle amplifying
neuron destruction referred to as reactive microgliosis could install
[143], whereby an acute insult can initiate a self-sustaining
inﬂammatory reaction maintained by a positive feedback from
dying neurons [138]. Interestingly, a-SYN aggregates [144] may
induce neuronal death through microglial activation as well.
4.1.2. The speciﬁc vulnerability of nigral dopaminergic neurons
The selective vulnerabilityofnigraldopaminergicneurons,which
represents less than 0.0001% of all brain neurons, could be attributed
to cell-speciﬁc risk factors. Brieﬂy, DA has been seen as a culprit,
because its metabolismwas shown to generate toxic reactive oxygenspecies (ROS) [145]. However, a variety of non-DA neurons also die in
PD and conversely some DA neuron populations are spared arguing
against DA as the principal cell-risk factor. Nigral DA neurons, as well
asotherneurons damagedinPD,have a distinctive impressive axonal
ﬁeld with disproportionally long unmyelinated axonal projections,
each of them supporting no less than 370,000 synapses [146].
Comparatively, SN DAergic cell body is small, representing about 1%
of the total cell volume [145]. Given their size and complexity, these
neurons are associated with an elevated axonal trafﬁcking and a high
ATP demand, which might sensitize them to proteostatic stress,
aggregation and energetic crisis. Thiscould explainwhy mutations in
genes related to mitochondrial and trafﬁcking activities could
predispose to PD. Moreover, adult SN DA neurons have a
particular and uncommon physiological phenotype. They are
neuronal pacemarkers, exhibiting an autonomous activity in the
absence of synaptic input to help maintaining DA levels in the
striatum, the main projection target. For that, they rely on relatively
rare L-type Ca2+ channels Cav1.3, which induce broader action
potentials. Contrasting with what occurs in the majority of neurons,
those channels are opened frequently with larger magnitude of
Ca2+ inﬂux [147]. The resulting Ca2+ overload could trigger chronic
cellular stress and be responsible for SN DA neuron speciﬁc
vulnerability. Any impairment in Ca2+ homeostasis regulation
mechanisms such as ATP-dependent pumping as well as
mitochondrial and endoplasmic reticulum adequate buffering
function might critically compromise SN DA neurons survival. These
neurons might additionally exhibit a lower intracellular Ca2+
buffering capacity sensitizing them to Ca2+ induced stress. They
are typically located in regions where calbindin, a Ca2+ fast buffering
protein, is poorly expressed, whereas neurons in calbindin rich
regions are relatively more resistant to death in PD [11,12]. Finally,
glutamatergic input to SN could also sensitize them to death through
excitotoxicity mediated by NMDA receptor activation [148].
4.2. PD diagnosis and biomarkers
Biomarkers are deﬁned as biological parameters that should be
objectively measurable, indicative of normal biological processes,
pathogenic processes or pharmacologic responses to a therapeutic
intervention (Biomarkers Deﬁnitions Working Group). Biomarkers
research in PD is still in its early stages and only few of the
investigated biomarkers have been validated for routine clinical
practice yet. PD diagnosis remains largely based on clinical criteria
and suffer from several limitations [149]. An early diagnosis was
proved particularly challenging due to an overlap of PD symptoms
with those of other forms of parkinsonism including multiple system
atrophy (MSA), progressive supranuclear palsy (PSP), dementia with
LB (DLB) or essential tremor [150,151]. Misdiagnosing was thus
frequently observed in the population at a rate of 15% [151] . However
when assessed by a movement disorder specialist, PD can be quite
accurately diagnosed during a patient’s life [152]. Moreover,
underdiagnosing rate was estimated at 20% in the population
receiving medical attention [151]. Unfortunately, a clinical diagnosis
of PD is necessarily postponed to an advanced pathological stage, as
about 60% of the nigral dopaminergic neurons are already lost at the
time of motor manifestations onset. Currently, a deﬁnitive diagnosis
of PD can only be made at autopsy, with the neuropathological
conﬁrmation of PD hallmarks. Hence sensitive, speciﬁc, non-
invasive and inexpensive PD biomarkers are needed to (i) detect
the disease early or even in preclinical phase and identify at-risk
individuals, (ii) provide an accurate and differential diagnosis to
distinguish PD from other related syndromes (iii) monitor disease
progression and the efﬁcacy of therapy. The following section gives
an overview of the most promising biomarkers available.
Recent advances in clinical, neuroimaging or molecular
biomarkers have improved the early and differential diagnosis of
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respectively detect hyposmia [153] or cardiac sympathetic denerva-
tion in PD – were developed for an early PD assessment, as nonmotor
impairments may precede motor manifestations [154,155].
Functional neuroimaging based on Positron Emission Tomography
(PET) or Single Photon Emission Computed Tomography (SPECT)
emerged to assess nigrostriatal dopaminergic terminal decline
[150,156,157] whereas transcranial ultrasonography allowed the
identiﬁcation of distinct hyperechogenicity patterns in the SN of
PD patients [158,159]. While promising these techniques still
demonstrate some limitations such as lack of sensitivity, speciﬁcity
or high costs hampering their widespread use as diagnostic
tests. Alternatively, a large number of biochemical compounds
(i.e., catecholamines, neuropeptides, amino acids, enzymes, IgGs,
oxidative stress proteins) including PD-related proteins (i.e., a-SYN,
DJ-1) were typically measured in CSF, blood or urine [160,161]
(Table 3). As a major component of LB, a-SYN was one of the most
attractive molecules to investigate. In plasma, levels of oligomeric
[162] and phosphorylated [163] a-SYN were found increased in PD
patients versus controls whereas in CSF, total a-SYN levels [164,165]Table 3
Potential biomarkers for sporadic Parkinson’s disease.
Biomarker Target Measurement method 
Clinical biomarkers
Progression on clinical scales Motor function Standard clinical criteria
(i.e., UKPDSBB, H&Y),
timed test (i.e., pegboard)
Olfactory deﬁcit Olfactory
function
Olfactory testing (UPSIT,
Snifﬁn’ sticks)
Imaging biomarkers
Cardiac sympathetic denervation Autonomic
function
123I-MIBG cardiac SPECT 
Loss of striatal DA or DAT decline Nigrostriatal
pathway
function
[18F]-ﬂuorodopa PET/DAT
SPECT
Nigralhyperechogenicity Substantia
nigra
Transcranial sonography 
Molecular biomarkers
Levels of:
&total a-syn (#)
&ratio oligo/ total a–syn (")
&DJ-1(#)
&Urate
CSF Immunoassay,enzymatic
assay
&Panel of proteins (i.e. DJ-1,a-syn,
total tau, phospho- tau, amyloid
b1–42, Flt3 ligand, and
fractalkaline)
CSF Immuno-assay (Luminex) 
Levels of:
&Oligomeric a-syn(")
& Phospho a-syn(")
&DJ-1 isoforms
&Urate
&Oxidative stress markers(")
Whole blood,
serum, plasma
or blood cells
Immuno-assay, enzymatic
assay
Levels of:
&8-OHdG
Urine Immuno-assay 
Levels of:
& a-syn, DJ-1
Saliva Immuno-assay 
Tissue immunoreactivity:
&a–syn
Peripheral
tissue biopsy
(i.e., colon,
skin)
Immunohistochemistry 
DAT, dopamine transporter; H&Y, Hoehn and Yahr scale; I-MIBG, 123-I- métaiodobenz
PSP, progressive supranuclear palsy; SPECT,single photon emission computed tomog
8-hydroxy-désoxyguanosine. Signs “+” and “” respectively indicate some of the advanwere found repeatedly decreased, although the increased
oligomers/total-a-SYN ratio found in PD might be more valuable
[166]. However, conﬂicting results, signiﬁcant overlap of values
between groups, insufﬁcient sensitivity and speciﬁcity preclude the
use of a-SYN as a valid marker at the moment [167]. Several studies
demonstrated inconsistent results regarding DJ-1 levels in the CSF,
whose combination with other molecule measurements might be
more helpful for PDdiagnosis [168]. Recently, aquantitative Luminex
assay demonstrated that the combination of a-SYN and DJ-1
measurements with ﬁve other molecules (total tau, phospho-tau,
amyloid b1–42, Flt3 ligand and fractalkine) in the CSF could not only
help in PD diagnosis and differential diagnosis but was also
correlated with disease progression and severity [169]. Given the
obvious role of oxidative stress in PD pathogenesis, oxidative
markers were investigated. For instance, urinary levels of
8-hydroxydeoxyguanosine were shown to be more elevated in PD
versus controls and able to evaluate disease progression [170].
Reduced levels of urate, a strong antioxidant, were found in serum,
CSF and in the SN of PD patients, which correlate with DA
neurodegeneration, advanced PD symptoms and higher risk forValue Reference
+: speciﬁcity, validated : insufﬁcient sensitivity, PD
diagnosis at late pathological
stage
[149,175]
+: early (pre-motor) and
differential PD diagnosis, low
cost
: insufﬁcient sensitivity and
speciﬁcity, correlation with
disease duration and severity?
[176,177]
+: differential diagnosis of PD,
early PD diagnosis?
: insufﬁcient sensitivity and
speciﬁcity, expensive
[178]
+:early PD diagnosis : insufﬁcient speciﬁcity,
modulated by DA drugs,
expensive
[179]
+: low cost, non-invasive : technically demanding,
disease progression?
[180]
+: non-invasive and promising
i.e., urate predictor of PD
progession?
: insufﬁcientsensitivity and
speciﬁcity , often inconsistent
results
[164–166,
168,171]
+: good sensitivity and
speciﬁcity, correlation with
disease progression and
severity
: not validated [169]
+: not invasive and promising : insufﬁcient sensitivity and
speciﬁcity, often inconsistent
results,
[162,163,171,
181–183]
+:non-invasive, predictor of
disease progression
: more evidence required [170]
+:non-invasive : more evidence required [184]
+:premotor PD detection :More evidence required [32,35,185]
ylguanidine; MSA, multiple system atrophy; PET, positron emission tomography;
raphy; UKPDSBB, UK Parkinson’s disease society brain bank criteria; 8-OHdG,
tages and drawbacks of each biomarker.
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the above biomarkers – taken individually or in combination – has
reached a sufﬁcient level of accuracy and reliability allowing their
clinical use [174].
5. Translational proteomics for Parkinson’s disease: from
benchside to the clinic
The recent emergence of new “candidate-free” unbiased
disciplines such as proteomics but also genomics and GWAS,
transcriptomics, or metabolomics has boost the exploration of new
avenues to decipher molecular pathways at the basis of PD
pathogenesis and biomarkers for PD diagnosis. Proteomics is a
particularly prominent “omic” discipline which systematically
studies the protein complement of cells or tissue at a given
time [186]. Around 20,000 human genes produce about 150,000
transcripts and more than 1,000,000 proteins as a results of
alternative splice variants, RNA editing or PTMs. At variance with
the static genome and limited transcriptome of a particular
biological structure, its proteome, which is submitted to constant
changes over time, represents a rich, if not inﬁnite, source of
information and a unique window into complex molecular
regulatory networks, as proteins are often the direct effectors
of biological systems. Proteomic analyses have allowed the
identiﬁcation and quantiﬁcation of thousands of proteins from
complex mixtures together with the determination of their
modiﬁcations (i.e., PTMs) or protein–protein interactions. A typical
workﬂow requires four consecutive steps: sample preparation,
protein/peptide separation, mass spectrometry (MS) analysis and
ﬁnally bioinformatics data processing. The most popular approach,
referred to as shotgun or bottom-up, involves the enzymatic
digestion of protein samples into peptides. After an overview of the
current proteomics methods, we will highlight some of the key
proteomic contributions to PD research. Given the current
limitations of animal models of PD, which still cannot recapitulate
all clinical and neuropathological features associated with
sporadic PD [85,187], this section will cover human sample-based
proteomic analyses only.Fig. 1. Potential samples of interest for PD translational proteomics. Line thickness is p
collected the more easily (minimally invasive procedure). In italic, samples which curr5.1. Proteomic methods
5.1.1. Sample processing prior to mass spectrometry
5.1.4.1. Sample choice and preparation. Because the availability of
tissue samples from disease sites is still limited, most proteomic
studies have relied on the analysis of autopsy tissues from various
brain structures as well as biological ﬂuids such as cerebrospinal
ﬂuid (CSF) or blood supposed to reﬂect the disease state (Fig. 1).
CSF is an excellent source of diagnostic biomarker as it is in close
proximity to the degenerating brain structures and may thus
directly reﬂect its biochemical state under pathological conditions.
CSF collection through lumbar puncture necessitates the
intervention of a trained specialist and is not without risk for
the patient, which may preclude its use for routine screening.
Blood – and its subcomponents plasma, serum and peripheral
mononuclear cells – can be easily obtained with very little
discomfort for the patient and is expected to reﬂect pathological
brain perturbations through disruption of or passage across the
blood–brain barrier. Blood analysis remains challenging given its
complexity, as blood proteins are derived from all perfused organs
and cell types, its high dynamic range of protein concentrations
which may vary by up to 1012, and the presence of a few highly
abundant proteins (i.e., 12 proteins) constituting most of the total
blood protein content (i.e., 95%) [188]. Urine and saliva have
sometimes been used in the ﬁeld of neurodegenerative disease
proteomics. Although they can be easily obtained and collected
non-invasively, their analysis is still associated to technical
difﬁculties due notably to their low protein content or high
inter- and intra-individual variability.
The preparation ofsuchsamplesnecessitatesspeciﬁc precautions
to prevent any analytical bias and allow reproducible comparisons
between samples especially regarding their collection, handling
and storage [189]. Because CSF protein content is low, blood
contamination is a central issue as it may dramatically affect CSF
protein levels and lead to conﬂicting results when measuring
biomarker levels such as a-SYN [167]. Storage temperature was
shown to affect protein levels as well. For instance, cystatin C was
shown to be degraded when CSF was stored at 20 C but not atroportional to sample accessibility, with the thicker line representing the samples
ently present the more technical limitations for a proteomics analysis.
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be taken to minimize post-mortem delay (PMD) – the time elapsed
between death and sample processing or freezing at 80 C, ideally
under48 h, at which most proteinmodiﬁcations mightoccurat room
temperature [191].
Efforts are generally placed into sample sub-fractionation at a
tissular, cellular or subcellular levels to target the most relevant
proteomes. CSF and blood can typically be depleted of their
few highest abundant proteins using immunoafﬁnity columns
(i.e., MARS column) to enrich in the many low abundant proteins
that could be potential markers of a pathological state. When using
autopsy samples, increasing levels of speciﬁcity can be assessed with
sub-proteome analyses of entire cryo-dissectedbrainregions such as
the cortex [192] or the SN [193–195] down to various sub-cellular
fractions of interest suchasmitochondria [196], synaptosomes[192],
cortical LBs [197,198] or neuromelanin granules [199] .
5.1.4.2. Sample separation. Given a proteome size, dynamics and
complexity in biological samples, its complete analysis represents a
considerable challenge which it is still not achievable using a single
method. Reducing sample complexity prior to MS analysis is
therefore an essential step, which requires thought-worthy
experimental design. A variety of methods were developed for
protein or peptide separation based on their physicochemical
properties, either by electrophoresis (i.e., SDS-PAGE, IEF, Offgel),
chromatography (i.e., SCX, RP) or immunoafﬁnity. Multidimensional
fractionation can be implemented to enhance proteome
coverage and detection sensitivity in MS. Two-dimensional gel
electrophoresis (2-DE) is a commonly used gel-based strategy
combining IEF and SDS-PAGE, which separates complex protein
samples according to their isoelectric point (pI) and molecular
weight [200]. A modiﬁed form of 2-DE termed difference gel
electrophoresis (DiGE) technology, allows sample multiplexing in a
single gel using ﬂuorescent dyes [201]. In contrast, gel-free
approaches are typically performed using liquid chromatographyFig. 2. Quantitative proteomic workﬂows. Proteins are extracted from biological samples
shotgun proteomic approach (B). In the 2-DE approach, protein spots are compared betw
interest are analyzed by tandem MS (MS/MS) for their identiﬁcation. In the shotgun appr
Results must be veriﬁed by at least one robust orthogonal method.(LC)-based techniques, which can directly be coupled with MS.
Chromatographic techniques involve protein or peptide separation
according to their hydrophobicity (i.e., reversed-phase columns),
ionic charge (i.e., SCX), size, afﬁnity (i.e., MARS column, IMAC
column). Informative subsets of proteins or peptides carrying
phosphorylations, glycations, glycosylations or being cysteine-rich
can thereby be isolated. Of note, a recently developed technique
termed Off- gel (OGE) allows the collection of peptide or protein
samples in liquid phase after IEF and is often coupled with LC.
5.1.2. Sample analysis by mass spectrometry
Mass spectrometry (MS) is the core component of proteomic
workﬂows allowing protein analysis through mass over charge (m/z)
measurements. Driven by the inextricable complexity of
proteomes, technical limits of MS instrumentation are constantly
pushed, with the development of multiple ion sources, analyzers or
detectors, the three main elements of mass spectrometers.
Matrix-assisted laser desorption/ionization (MALDI) [202] and
electrospray ionization (ESI) [203] are generally used in proteomics
in combination with a variety of mass analyzers including time of
ﬂight (TOF), ion trap (IT), quadrupole (Q), Fourier transform
ion cyclotron resonance (FTICR) or Orbitrap. Hybrid mass
spectrometers enable the determination of protein amino acid
sequence, expression level and structural features (i.e., PTM sites)
using multiple stage MS fragmentation (MSn). Ion fragmentation is
generally done by collision induced dissociation (CID) but electron
transfer dissociation (ETD) may be more suited to analyze PTMs
[204]. The ESI linear trap quadrupole (LTQ)-Orbitrap is one of
the most performant and recent instrument commercialized,
combining the MSn capability of the LTQ with the high resolution
and mass accuracy of the Orbitrap [205–207].
Several bioinformatics tools were developed to interpret
MS data. These include tools for peptide/protein identiﬁcation
(i.e., Mascot [208], Phenyx [209]) or PTMs analysis (i.e., Quickmod
[210]) based on sequence database search algorithms as well as tools and can either be submitted to a 2-DE workﬂow (A) or digested and submitted to a
een gels using an image analysis software allowing their quantiﬁcation, and spots of
oach, differentially labeled peptide samples are identiﬁed and quantiﬁed by MS/MS.
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protein/peptide identiﬁcation is a probability based process, false
discovery rates (FDR) are generally calculated to estimate the rates of
mistakenly identiﬁed proteins and should generally be kept below
1% at the peptide or protein level [212]. When peptide or protein
sequences are absent from databases, often resulting from
unexpected PTMs, de novo peptide sequencing can be performed
manually or using speciﬁc programs.
5.1.3. Quantitative proteomics
Quantitative proteomic data are needed to determine the
speciﬁc set of proteins exhibiting different expression levels in
healthy versus pathological states. Relative quantiﬁcation has
traditionally been performed by 2-DE or DIGE, followed by staining
and image analysis to identify differences in gel patterns (Fig. 2).
Although providing access to a range of PTMs and protein isoforms,
the procedure is not best-suited for the rapid analysis of complex
samples, suffering principally from a lack of automatization and a
limited dynamic range together with reproducibility, resolution
and sensitivity issues. Alternatively, high throughput shotgun
quantitative proteomic platforms coupled with multidimensional
LC has been widely used to tackle complex mixtures, either relying
on isotope labeling of proteins or peptides, or “label-free” with
quantiﬁcation based on spectral counting or ion peak intensity
[213].While the latter could be more convenient for analyzing large
number of samples (ex. clinical screening), it strongly relies on
robust sample preparation procedures and may be less reliable for
measuring small protein changes [214,215] .
Most proteomic quantitative analyses are thus based on
isotope labeling, which consists in the introduction of a mass
tag (i.e., heavy or light) to differentiate identical peptides from
various samples in MS owing to a mass shift. Isotope labeling can
be done at various levels (i.e., cell, protein, peptide) on different
reactive groups (i.e., cysteine, lysine containing residues) and allow
sample multiplexing. During the past years, several methods were
developed including stable isotope metabolic labeling for cultured
cells (SILAC), isotope-coded afﬁnity tags (ICAT) or isobaric tagging
technologies either using tandem mass tags (TMT) [216,217] or
isobaric tags for relative and absolute quantiﬁcation (iTRAQ)
[218,219]. In isobaric labeling, the total mass of the tag is kept
constant owing to a mass normalizer group, and identical peptides
from different samples sharing the same chromatographic
properties co-elute in the mass spectrometer. Labeled peptides
thus appear at the same mass in an MS scan, but give rise to low
mass reporter signature ions upon CID fragmentation in MS/MS
mode (i.e., between 126 and 131 m/z for TMT-6). This robust
approach has been one of the most beneﬁcial for the analysis of
body ﬂuids and tissues as it allows the simultaneous peptide
identiﬁcation and quantiﬁcation of up to 10 samples in a single
MS/MS experiment. The comprehensive analysis of speciﬁc PTMs
known to be important for PD, such as oxidation, nitration,
phosphorylation, glycosylation or ubiquitination can also be
addressed. Generally, proteomes of interest are speciﬁcally
enriched before being analyzed by MS quantitative techniques.
Alternatively, peptides with deﬁned PTMS can be targeted based
on their MS fragmentation characteristics (i.e., neutral loss,
multiple reaction monitoring MS modes). Selected Reaction
Monitoring (SRM) allows the targeting and measurement of
selected signature peptides from molecules of interest (reviewed
in [220]). Given its unique potential to quantify reliably low
abundant analytes in complex mixtures, SRM may represent an
alternative to ELISA for clinical validation measurements which
are dependent on antibody availability. Importantly, absolute
quantiﬁcation can be obtained through AQUA method, with the
spiking of a known quantity of an isotope- labeled peptide as an
internal standard, followed by SRM MS analysis [221].5.2. Translational proteomic
5.2.2. The quest for PD biomarkers
To date, the clinical management of PD patients is still hampered
by the lack of reliable diagnostic and therapeutic biomarkers which
might pave the way for the development of better options and PD
treatment and prevention. Traditional candidate-based studies have
assessed the potential of speciﬁc targets typically associated to PD
pathophysiology as biomarkers of PD, for example the CSF level of
a-SYN. In contrast, unbiased biomarker discovery using “omics”
technologies such as proteomics has allowed the detection invarious
human samples of a wide panel of pathological protein expression or
PTMs changes, which could serve as novel biomarkers.
In PD, most biomarker discovery studies have relied on the
proteome analysis of CSF. Using 2-DE, CSF proﬁling allowed the
detection of a few differential proteins (i.e., complement c3)
between control and PD patients [222,223]. Much more changes
were detected in the CSF composition of PD patients using shotgun
proteomic quantitative strategies as reviewed in [224]. Abdi et al.
found 72 proteins – including ceruloplasmin or apolipoprotein H,
uniquely associated to PD compared to AD, dementia with LBs and
control patient samples differentially labeled with iTRAQ-4plex
[218]. Based on these results, Zhang et al. performed a large-scale
validation of their best potential candidates using a Luminex assay
and found that a panel of eight proteins (i.e., tau, amyloid b-42,
b-2 microglobulin, interleukin- 8, vitamin D binding protein,
apolipoproteins A-II and E and BDNF) was highly effective at
identifying PD [225]. The proteomic analysis of plasma and serum
samples was proved challenging considering their complexity and
the presence of a few highly abundant proteins. However, recent
studies successfully highlighted potential PD biomarkers in blood
[226–228], of which the most promising may be plasma
apolipoprotein A1 (ApoA1) [227]. This result was conﬁrmed by
independent studies based on multiplex and ELISA immunoassays,
which suggested that low ApoA1 levels correlated with early PD
onsetandgreaterdopaminergicdeﬁcitasmeasuredby putaminalDA
transporter binding [229]. Alternatively, peripheral blood lympho-
cytes were investigated, highlighting a panel of ﬁve proteins (coﬁlin,
tropomyosin, gamma-ﬁbrinogen, ATP synthase beta and basic actin
variant), which may be useful for PD diagnosis [230].
In the future, other sources of potential biomarkers accessible
in vivo may be investigated by proteomics (Table 1, Table 3).
Moreover, as shown on Fig. 1, tissue biomarkers may be found in
peripheral regions susceptible to Lewy pathology such as
submandibulary gland, colon, or skin [50,53,185,231]. These
regions could be accessed through biopsy in living patient and
could allow the detection of early disease biomarkers, as the
peripheral nervous system may be involved before the central
nervous system in PD. Saliva was recently analyzed given its
connection to the submandibular gland, which produces most of
the salivary volume [29]. Importantly, a-SYN and DJ-1 were
successfully identiﬁed in saliva, providing further relevance for the
study of this ﬂuid in a biomarker context [184]. Finally, unbiased
proteomics investigations of post-mortem tissues from selected
PD-relevant brain regions of neuropathologically conﬁrmed cases
might provide useful candidate biomarker proteins, which could
further be screened in bioﬂuids using immunoassay or targeted
proteomics such as SRM. This approach is expected to provide
highly speciﬁc PD markers given its direct access into PD
pathological sites in neuropathologically conﬁrmed PD cases.
5.2.3. Improving PD pathogenesis understanding
Effective therapeutic interventions directly impacting PD biology
are urgently needed to slow, interrupt or ideally reverse the
inexorable progression of the neurodegenerative process. Advances
in the understanding of the speciﬁc pathological actors mediating
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new avenues for treatment and perhaps prevention of the disease.
Although helpful, hypothesis-driven or “candidate-based”
approaches might have reached some limits in the understanding
of PD pathology, overwhelmed by the impressive complexity and
diversity of the processes likely engaged in PD. In the last 10 years,
unbiased proteomic studies have been undertaken in human
PD-relevant brain regions to gain new insights into PD pathogenesis.
Autopsy tissues were generally used, allowing the analysis, in
neuropathologically conﬁrmed cases, of the key brain structures
selectively affected in PD, which are not accessible to in vivo biopsy.
Although taken at a late pathological stage, these samples may
provide a unique window into the speciﬁc abnormalities occurring
in PD brains in the absence of any validated PD animal model.
However, only a small number of studies have been published as yet
due to the scarcity of human tissue samples available.
5.2.4. Characterizing brain proteomes
Proteomic proﬁling of PD-relevant brain regions has generated
the identiﬁcation of extensive protein datasets, whose
characterization has helped to understand their speciﬁc functions
within the CNS and their particular vulnerability in PD. In a recent
shotgun proteomics study, our group established the more
comprehensive catalog of nigral proteins with 1795 identiﬁcations
in PD and control patients [232]. The GO analyses suggested a
critical involvement of high energetic supply, anti-oxidant defense,
cytoskeletal organization and vesicular transport in SN function. As
PD lesions extend towards cortical regions at advanced disease
stages, the proteome of frontal cortex was characterized, leading
to 812 protein identiﬁcations in cytosolic, mitochondrial,
synaptosomal or nuclear fractions. Many of those proteins
appeared to be involved in neurodegenerative diseases [233]. To
dig deeper into the brain proteome, the content of subcellular
fractions were examined. Leverenz et al. managed to analyze 20 500
cortical LB isolated by laser capture microdissection from patientsFig. 3. Proteomics conﬁrmed existing hypotheses surrounding PD pathogenesis and hig
represent proteins found respectively over- and under-expressed in PD.with dementia with LB disease, discovering 296 proteins [197].
Although a few proteins were validated by IHC localization, future
investigations may exclude contamination from the surrounding
tissues. Another group used a sucrose gradient centrifugation
strategy to enrich cortical LB from LB variant of AD, yielding to the
identiﬁcation of 40 proteins which were not present in a negative
control [198]. Altogether, these studies may help to decipher the
mechanisms of LB formation and the pathways leading to
neurodegeneration in PD. Tribl et al. carried out the ﬁrst proteomic
proﬁle of intact neuromelanin (NM) granules enriched from
control human SN using density gradient centrifugation [199].
Seventy-two proteins were identiﬁed, of which many were closely
linked to lysosome-related organelles [199]. Of note, the protocol
has been recently improved to allow the combined enrichment of
neuromelanin and synaptosomal fractions using far less starting
material (<0.15 g) [234]. This important development may allow
collecting a sufﬁcient amount of NM from PD patient nigral
tissues, which are severely depleted in NM-containing cells.
A link between NM and PD pathogenesis was hypothesized as
NM-containing neurons seem to be more vulnerable in PD [235].
Moreover, NM interacts with iron, which is known to accumulate
in the parkinsonian SN. Recently, a targeted proteomic approach
revealed that L-ferritin was an NM granule component, providing
new clues on iron storage mechanisms in the NM-containing
neurons [236]. These investigations provided insights into NM
composition, mechanisms and function, which are still poorly
characterized, and may help to understand iron-driven
degeneration of the SN in PD.
5.2.5. Identifying proteome alterations in PD brains
To gain more insights into the disease pathogenesis, quantitative
proteomic data may allow the complex proteome alterations
occurring in the brains of PD versus control patients to be
disentangled. 2-DE studies of human brain tissues targeting the
SN were conducted, highlighting several abnormalities in thehlighted less conventional ones (image modiﬁed from [232]). Red and blue colors
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able to identify CNDP2 or VPS29 overexpression in PD. Using a
shotgun approach combined to ICAT, others found 119 proteins
exhibit changesintheir relative expression inmitochondrial fractions
obtained from the SNpc of PD cases compared to controls [196]. Of
these, mortalin decrease in PD was conﬁrmed using a cellular PD
model and functional biology experiments suggested a major role for
mortalin in PD neurotoxicity through mechanisms that may involve
oxidative stress, mitochondrial and proteasomal dysfunction [196].
Taking advantage of the sixplex TMT tagging technology to compare
the nigral proteome of PD patients (n = 3) versus controls (n = 3), our
group observed signiﬁcantexpressionlevel changes in 204 proteins.
PD-relevant candidates were further characterized including
nebulette, whose overexpression might be associated to neuro-
degeneration in PD through mechanisms that may involve
disruption of cytoskeletal dynamics [232].
A few proteomic comparative studies have focused on
post-mortem cortical tissues. Two studies using iTRAQ labeling to
proﬁle frontal cortex samples of PD patients at different stage of the
disease and control cases, suggested a potential association of
respectively mortalin and glutathione-S transferase Pi (GSTP1) with
disease progression [192,237]. In the ﬁrst study, mortalin under-
expression was observed in the cytosolic fraction of PD patients and
validated by independent methods [237]. In the second study, GSTP1
overexpression was observed in the synaptosomal fraction of PD
cases and was suggested to protect cells against rotenone-induced
neurotoxicity via oxidative and ER stress attenuation in a PD cell
model [152]. Three other studies by Choi et al. proved useful for
elucidating some of the PTMs associated with PD. Using 2-DE, they
demonstrated oxidation in multiple proteins previously linked to PD,
includingthechaperone DJ-1,superoxidedismutaseCu/Zn, aswellas
the de-ubiquitinating protein UCH-L1 in the frontal cortex of PD
patients compared to controls [238–240]. Recently, van Dijk et al.
performed a proteomic analysis of the locus ceruleus, one of the
earliest affected brain regions in PD [241]. By comparing PD patients
(n = 6) versus controls (n = 6) with a label free approach, they
identiﬁed 20 495 proteins of which 87 were differentially expressed
between groups. In particular, a pathogenic role for aminoacyl-
tRNA-biosynthesis was highlighted.
Overall, these proteomics studies were successful in conﬁrming
existing theories about PD pathogenesis (Fig. 3). The majority of
the differential proteins were indeed implicated in mitochondrial
dysfunction, energy metabolism impairment, oxidative stress,
protein aggregation, cytoskeleton impairment, or inﬂammation.
Whereas some of the observed protein alterations were previously
associated to PD pathogenesis (i.e., ferritin), others were novel
candidates such as CNDP2, mortalin, regucalcin, or seipin.
Curiously, a-SYN overexpression did generally not show up
signiﬁcantly in these studies [196,232,241]. The most probable
explanation comes from the fact that in a tissue-based approach,
the overexpression of synaptic a-SYN in surviving DA neuronal PD
cells may be compensated by the higher number of healthy
neuronal cells in control patients. These studies also suggested
some less conventional pathways such as defects in protein
translation, ER stress, blood brain barrier or extracellular matrix
abnormalities (Fig. 3). Of note, it was sometimes unclear whether
the observed protein changes were a cause or a consequence of the
neurodegenerative process. In tissue-based approach, the decrease
in neuronal protein levels may simply reﬂect PD associated
neuronal loss. Further biological evaluation of the pathogenic
mechanisms underlying these protein alterations may provide
new therapeutic targets for PD.
5.2.6. Some perspectives
During the past 10 years, only a small number of human tissue
based proteomics studies have been published due to limitations intheir availability, number, quality and complexity. In the context of
a worldwide decline in autopsy rate, some of these issues can be
partially overcome through a facilitated access to existing brain
banks which ensure the collection of well characterized and
preserved brain tissues. There are probably over a hundred brain
banks worldwide, an incomplete list of which can be accessed at
the BrainNet Europe website (http://www.brainnet-europe.org).
Moreover, a novel technology might allow the molecular
imprinting of basal ganglia tissues obtained during deep brain
stimulation (DBS) from living PD patients. Taking advantage of the
temporary access to speciﬁc target regions during the implantation
of DBS electrodes for PD treatment, the approach may allow the
capture of small tissue amounts (i.e., about 20 mg of proteins) using
a chemically modiﬁed micro silicon chip placed at the tip of the
surgical dilator, as demonstrated in monkeys [242]. If applicable to
humans, the use of in vivo brain tissue imprints would reduce PMD
to a few minutes avoiding protein degradation and may allow
the observation of changes occurring early in PD course,
although control samples might be more difﬁcult to obtain for
comparisons. Finally, the great complexity and cellular
heterogeneity characterizing human brain regions may be further
addressed by additional cellular and subcellular fractionation
steps. In the SN, mixed cell populations together with the
characteristic neuronal DA loss in PD may have obscured the
identiﬁcation and quantiﬁcation of subtle changes limited to DA
neurons. Laser- capture microdissection (LCM) together with the
emergence of more sensitive MS techniques and automated
methods to collect cells offer now the possibility to speciﬁcally
isolate and investigate separately small deﬁned areas including
neurons, facilitating data interpretation. The selective dissection of
DA neurons neurons by LCM might allow to dig deeper in the
DA neuron proteome and to reveal the speciﬁc pathological
mechanisms responsible for their demise in PD.
5.2.7. Concluding remarks
Somewhat disappointingly, comparative proteomic studies have
received little attention from the neuroscience community yet. This
mightbe due to several factors including the absence of well- deﬁned
hypotheses and the low concordance rates observed between
studies. It is generally difﬁcult to compare proteomic studies
together, as many sources of variability can drastically inﬂuence
the ﬁnal outcome. First, samples themselves are greatly
heterogeneous, asa consequenceof patient’s history, co-morbidities,
PD subtype, disease duration or therapies, all hardly controllable
parameters. Tissue quality can also affect protein changes, when
PMD delays are too long or different between groups. Second, the
lack of standardized protocols for sample handling, preparation
(i.e., dissection, solubilization buffers) and analysis may prevent
inter-laboratory comparisons as well. In fact, the plethora of existing
analytical methodsmayleadtovariabilityinthe identiﬁedproteome.
This translates into small overlaps in protein identiﬁcations across
proteomic studies. For example, more than 1200 nigral proteins of
our recently identiﬁed dataset were not identiﬁed in the few other
proteomic investigations studying SN [193,195,196]. Third, the
generally small number of samples examined by proteomics is
associated with a low statistical power for detecting differentially
expressed proteins. The lack of stringent criteria to select differential
proteins together with the absence of further result validation, an
almost impossible task given the usually large differential protein
datasets, may lead to the identiﬁcation of false positives and false
negative candidates. Consequently, only a small percentage of
proteins were found similarly differential across the few proteomic
studies analyzing SN for instance, although a high proportion of
non-differential proteins were concordant between them. The fact
that differential proteins are sometimes found inversely expressed
across studies may indicate the presence of different protein
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mechanism. Indeed, PD is known to be a heterogeneous disease
and distinct alterations in common pathways may induce a
common phenotype. For example, different point mutations and
multiplications of a-SYN all result in familial PD. Similarly to what is
generally thought for transcriptomic data, the absence of
concordance between proteomic studies could be due to the
utilization of protein list for comparisons, rather than standardized
pathways, which could indicate the involvement of common
pathogenic mechanisms. To conclude, instead of being taken as
conﬂictual, results obtained in proteomics may rather be seen
globally, each proteomic study identifying a fraction of the changes
occurring in the SN and contributing step-by- step to a better
knowledge of the extraordinarily complex molecular jigsaw puzzle
at the basis of PD.
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